Spondyloarthritis The Changing Landscape Today An Issue Of Rheumatic Disease Clinics Of North America

This issue of Rheumatic Disease Clinics, guest edited by Drs. Xenofon Baraliakos and Michael H. Weisman, Spondyloarthritis: The Changing Landscape Today, takes a very comprehensive look at all of the essential topics surrounding spondyloarthritis. This issue is one of four selected each year by Dr. Weisman, who is also our series consulting editor. This very comprehensive issue will include the following topics (among others): Molecular biology approaches to understanding SpA; Microbiome and its role in SpA; Classification criteria in axSpA; Administrative data and coding for axSpA; Approach to the patient with IBD and AxSpA; Axial PsA vs. Axial SpA with Psoriasis; Emerging imaging techniques in SpA; The future of imaging in axSpA; Treatment Recommendations vs. Treat to Target in axSpA; The future of axSpA treatmentAxSpA in the era of Precision Medicine; Quality of Life as an outcome in studies of axSpA; Gender differences in SpA; The patient’s perspective on the burden of disease in axSpA; and Juvenile SpA.

This issue of Rheumatic Disease Clinics, guest edited by Drs. Xenofon Baraliakos and Michael H. Weisman, Spondyloarthritis: The Changing Landscape Today, takes a very comprehensive look at all of the essential topics surrounding spondyloarthritis. This issue is one of four selected each year by Dr. Weisman, who is also our series consulting editor. This very comprehensive issue will include the following topics (among others): Molecular biology approaches to understanding SpA; Microbiome and its role in SpA; Classification criteria in axSpA; Administrative data and coding for axSpA; Approach to the patient with IBD and AxSpA; Axial PsA vs. Axial SpA with Psoriasis; Emerging imaging techniques in SpA; The future of imaging in axSpA; Treatment Recommendations vs. Treat to Target in axSpA; The future of axSpA treatmentAxSpA in the era of Precision Medicine; Quality of Life as an outcome in studies of axSpA; Gender differences in SpA; The patient's perspective on the burden of disease in axSpA; and Juvenile SpA.

Edited by Drs. Juergen Braun and Joachim Sieper, this issue of Rheumatic Disease Clinics comprehensively reviews the state of the art of spondyloarthritis (SpA) diagnosis, prognosis, pathogenesis and genetic insights, and treatment. The worldwide burden of SpA now exceeds that of rheumatoid arthritis. General topics covered include inflammatory back pain, pathophysiology, imaging techniques, and therapeutic strategies.

This issue of Rheumatic Disease Clinics, edited by Drs. John Imboden and Sarah Goglin, will cover a variety of important aspects of the neurological manifestations of rheumatic diseases. Topics discussed in the issue will include: Primary vasculitis of the central nervous system; Neurologic manifestations of primary Sjogren Syndrome; Neurologic manifestations of antiphospholipid antibody syndrome; Neurologic manifestations of rheumatoid arthritis and ankylosing spondylitis; Neuromyelitis optica; Neurosarcoid; Central nervous system infections associated with immunosuppressive therapy; and Neurologic manifestations of IgG4-related disease, among others.

Guest edited by Drs. Daniel J. Wallace and R. Swamy Venuturupalli, this issue of Rheumatic Disease Clinics will cover several key areas of interest related to Best Practices and Challenges to the Practice of Rheumatology. This issue is one of four selected each year by our series Consulting Editor, Dr. Michael Weisman of Cedars-Sinai. Articles in this issue include, but are not limited to: The Economics of Rheumatology Practice in the United States, Manpower trends in rheumatology, Challenges to practicing rheumatology in an academic center, Challenges in practicing rheumatology in a government setting, Challenges to practicing rheumatology in a small private practice setting, Challenges to working in a large multispecialty organization, Challenges to practicing pediatric rheumatology, Clinical trials in rheumatology, Challenges in having an infusion center, Implementing treatment to target in the clinic, Future directions: implementing new technologies in clinical practice, Possible Challenges in Optimizing Medical Education for Rheumatologists, and the challenges of approaching and managing gout.

Guest edited by Dr. Brian Mandell, this issue of Medical Clinics of North America will cover several key areas of interest related to Rheumatology. This issue is one of six selected each year by our series Consulting Editor, Dr. Jack Ende. Articles in this issue include but are not limited to: Vaccinations in Patients with Rheumatic Disease: Consider Disease and Therapy, Rheumatic Complications of Immune Checkpoint Inhibitors, Managing the Cardiovascular Risk in Patients with Rheumatic Disease, Statin associated myalgias and muscle injury – recognizing and managing both while still lowering the low-density lipoprotein, Perioperative Management of Rheumatic Disease and Therapies, Fibromyalgia: Recognition and Management in the Primary Care Office, Management and Cure of Gouty Arthritis, Update on the Treatment of Giant Cell Arteritis and Polymyalgia Rheumatica, Suspecting and Diagnosing the Patient with Spondyloarthritis and What to Expect from Therapy, Pregnancy and Management in Women with Rheumatoid Arthritis, Systemic Lupus Erythematosus and Obstetrical Antiphospholipid Syndrome, Rheumatoid Arthritis: Early Diagnosis and Treatment, Management of Knee Osteoarthritis: What Internists Need to Know, Antinuclear antibody (ANA) testing for the diagnosis of Systemic Lupus Erythematosus (SLE), and more.

Guest edited by Drs. Jonathan Kay and Sergio Schwartzman, this issue of Rheumatic Disease Clinics will cover Controversies in Rheumatology. This issue is one of four selected each year by our series Consulting Editor, Dr. Michael Weisman of Cedars-Sinai. Articles explore several questions, including, but not limited to: Is triple therapy or methotrexate plus a biologic the initial treatment of choice for RA patients; Is hypo or hyper-uricemia a risk requiring treatment for cardiac morbidity and mortality; Are there benefits and risks to biosimilars from a patient perspective; Should platelet-rich plasma be used to treat osteoarthritis; Is there a role for stem cell therapy to treat cartilage defects in osteoarthritis; Should any rheumatology patient, today, be treated with bone marrow ablation and stem cell transplantation; Is there effective prevention, prophylaxis, or treatment for CPPD arthritis; Is fibromyalgia a psychiatric disease or a pain syndrome; Should cyclophosphamide still be used to treat ANCA-associated vasculitis; Does methotrexate have a place in the treatment of psoriatic arthritis; Should hydroxychloroquine dosing be limited because of potential ocular toxicity; and Should generalized immunosuppression or targeted organ treatment be the best principle for overall management of SLE.

Edited by Drs. Juergen Braun and Joachim Sieper, this issue of Rheumatic Disease Clinics comprehensively reviews the state of the art of spondyloarthritis (SpA) diagnosis, prognosis, pathogenesis and genetic insights, and treatment. The worldwide burden of SpA now exceeds that of rheumatoid arthritis. General topics covered include inflammatory back pain, pathophysiology, imaging techniques, and therapeutic strategies.